Kiadis Pharma receives two orphan drug designations for Reviroc from the FDA
10-Dec-2008
- USA
“This is an important strategic milestone in the development of Reviroc™ and we are very pleased with the orphan drug designations received from the FDA”, says Dr. Manja Bouman, Chief Executive Officer of Kiadis Pharma.
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.